Astex Transfers Anticancer Epigenetics Collaboration to Partner GSK

Astex Pharmaceuticals has passed all assets relating to its Climb anticancer epigenetics collaboration to GlaxoSmithKline (GSK), its existing partner in the project. The collaboration was initiated between SuperGen and GSK in 2009, but following Supergen’s 2010 purchase of Astex Therapeutics, a strategic pipeline and drug discovery program review has led the newly named Astex Pharmaceuticals to transfer the program to GSK.
Genetic Engineering & Biotechnology News